ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Phase 3HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions

Panzyga, 10% Intravenous SolutionPlacebo

Octapharma360 participants6 sites · United States, Bulgaria, LatviaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants18 sites · United States, Japan, SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Phase 3Rheumatoid Arthritis (RA)

MB04 (proposed biosimilar to etanercept)Enbrel (etanercept)

mAbxience Research S.L.458 participants60 sites · Bulgaria, Georgia, MoldovaCompletes Oct 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

1–15 of 39

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Phase 3HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions

Panzyga, 10% Intravenous SolutionPlacebo

Octapharma360 participants6 sites · United States, Bulgaria, LatviaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Phase 2Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)

BCMA-CD19 CAR-T therapy

Peking University People's Hospital50 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants18 sites · United States, Japan, SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Phase 3Rheumatoid Arthritis (RA)

MB04 (proposed biosimilar to etanercept)Enbrel (etanercept)

mAbxience Research S.L.458 participants60 sites · Bulgaria, Georgia, MoldovaCompletes Oct 2025

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

1–15 of 39